KR100322208B1 - 7-디하이드로콜레스테롤을 함유하는 화장료 조성물 - Google Patents
7-디하이드로콜레스테롤을 함유하는 화장료 조성물 Download PDFInfo
- Publication number
- KR100322208B1 KR100322208B1 KR1019990022017A KR19990022017A KR100322208B1 KR 100322208 B1 KR100322208 B1 KR 100322208B1 KR 1019990022017 A KR1019990022017 A KR 1019990022017A KR 19990022017 A KR19990022017 A KR 19990022017A KR 100322208 B1 KR100322208 B1 KR 100322208B1
- Authority
- KR
- South Korea
- Prior art keywords
- dihydrocholesterol
- cosmetic composition
- skin
- polymer resin
- stabilized
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000002952 polymeric resin Substances 0.000 claims abstract description 20
- 229920003002 synthetic resin Polymers 0.000 claims abstract description 20
- 230000037303 wrinkles Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 229920006243 acrylic copolymer Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000009759 skin aging Effects 0.000 abstract description 9
- 230000000087 stabilizing effect Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- 235000005282 vitamin D3 Nutrition 0.000 description 5
- 239000011647 vitamin D3 Substances 0.000 description 5
- 229940021056 vitamin d3 Drugs 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 230000006750 UV protection Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- DNVPQKQSNYMLRS-PAWLVPEASA-N (3s,9r,10r,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-PAWLVPEASA-N 0.000 description 1
- DNVPQKQSNYMLRS-OJBTWCRJSA-N (3s,9s,10s,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-OJBTWCRJSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000220645 Leonotis nepetifolia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- -1 lumysterol Chemical compound 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/20—Disintegrating members
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C11/00—Other auxiliary devices or accessories specially adapted for grain mills
Landscapes
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Cosmetics (AREA)
Abstract
Description
배합성분 | 실시예 1함량 | 실시예 2함량 | 비교예 1함량 | 비교에 2함량 | |
가 | 7-디하이드로콜레스테롤아크릴릭/아크릴코폴리머알코올레티놀 | 0.102.0020.000.00 | 0.102.0020.000.00 | 0.100.000.000.00 | 0.000.000.000.10 |
나 | 부틸렌글리콜세탄올옥틸도데칸올글리세롤스테아레이트솔비탄세스퀴올레이트카르복시폴리머트리에탄올아민방부제향료색소정제수히포타우린 | 7.001.007.000.700.500.300.30적량적량적량잔량0.10 | 7.001.007.000.700.500.300.30적량적량적량잔량0.00 | 7.001.007.000.700.500.300.30적량적량적량잔량0.10 | 7.001.007.000.700.500.300.30적량적량적량잔량0.00 |
계 | 100.00 | 100.00 | 100.00 | 100.00 |
7-디하이드로콜레스테롤 함유량(%) | |||
실시예 1 | 실시예 2 | 비교예 1 | |
제조직후 | 99 | 100 | 99 |
2주후 25℃ | 99 | 99 | 72 |
2주후 45℃ | 96 | 97 | 43 |
4주후 45℃ | 93 | 97 | 21 |
자외선 25℃ | 95 | 98 | 32 |
자외선 45℃ | 91 | 96 | 17 |
방어효과 | |
실시예 2 | 63% |
비교예 1 | 55% |
음성대조군 | 56% |
현저한 효과 | 완화효과 | 효과없음 | |
실시예 2 | 22 | 8 | 0 |
비교예 1 | 3 | 9 | 18 |
현저한 효과 | 완화효과 | 효과 없음 | |
실시예 2 | 9 | 11 | 0 |
비교예 1 | 2 | 5 | 13 |
Claims (13)
- 삭제
- 삭제
- 알콜에 용해시킨 7-디하이드로콜레스테롤에분자량 1000-1,000,000의 아크릴릭/아크릴 코폴리머로 구성된다공성의 친유성 고분자 수지를 첨가하여 상기 7-디하이드로콜레스테롤을 상기 고분자 수지에 흡착시킨 후, 상기 알콜을 휘발시키고 나서 고분자 수지 세공에 7-디하이드로콜레스테롤을 고착시키는 단계를 포함하는 방법에 의해 안정화된 7-디하이드로콜레스테롤을 포함하고, 이 때, 전체 중량에 대하여 상기 7-디하이드로콜레스테롤을 0.0001 내지 10중량%를 함유하고, 상기 다공성인 친유성 고분자를 0.01 내지 30중량% 함유한 것을 특징으로 하는, 안정화된 7-디하이드로콜레스테롤을 포함하는 화장료 조성물.
- 삭제
- 삭제
- 삭제
- 제3항에 있어서, 그 제형이 영양크림, 마사지크림, 엣센스 및 팩 중에서 선택된 1종인 것을 특징으로 하는 화장료 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 제3항에 있어서, 주름완화기능을 가지는 것을 특징으로 하는, 안정화된 7-디하이드로콜레스테롤을 포함하는 화장료 조성물.
- 제3항에 있어서, 자외선 방어효과를 가지는 것을 특징으로 하는, 안정화된 7-디하이드로콜레스테롤을 포함하는 화장료 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990022017A KR100322208B1 (ko) | 1999-06-14 | 1999-06-14 | 7-디하이드로콜레스테롤을 함유하는 화장료 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990022017A KR100322208B1 (ko) | 1999-06-14 | 1999-06-14 | 7-디하이드로콜레스테롤을 함유하는 화장료 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010002281A KR20010002281A (ko) | 2001-01-15 |
KR100322208B1 true KR100322208B1 (ko) | 2002-02-07 |
Family
ID=19592032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990022017A KR100322208B1 (ko) | 1999-06-14 | 1999-06-14 | 7-디하이드로콜레스테롤을 함유하는 화장료 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100322208B1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100473716B1 (ko) * | 2002-03-27 | 2005-03-08 | 주식회사 참 존 | 7-디하이드로콜레스테롤 및 사이클로덱스트린의 포접복합체, 이를 포함하는 화장료 조성물 및7-디하이드로콜레스테롤의 안정화방법 |
KR101701382B1 (ko) | 2014-01-29 | 2017-02-01 | 주식회사 휴메딕스 | 페길레이션된 7-디하이드로콜레스테롤 유도체 |
KR101702076B1 (ko) * | 2015-02-25 | 2017-02-02 | 주식회사 휴메딕스 | 지방산 컨쥬게이션된 7-데하이드로콜레스테롤 유도체 |
KR101975387B1 (ko) * | 2017-02-14 | 2019-05-10 | 휴먼코스메틱 주식회사 | 프로비타민 d3을 함유하는 자외선 차단용 화장료 조성물 |
KR102078667B1 (ko) | 2018-06-18 | 2020-02-19 | 주식회사 고운세상코스메틱 | 7-데하이드로콜레스테롤, 콜레스테롤 및 스테아린산이 히알루론산-세라마이드 엔피 복합체의 내상에 봉입된 나노에멀젼을 함유하는 화장료 조성물 및 그의 제조방법 |
KR102557749B1 (ko) * | 2020-12-23 | 2023-07-21 | 주식회사 고운세상코스메틱 | 피부 장벽 개선, 보습 및 혈중 비타민 d 수치 개선 효과가 우수한 화장료 조성물 |
-
1999
- 1999-06-14 KR KR1019990022017A patent/KR100322208B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20010002281A (ko) | 2001-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2501544C2 (ru) | Композиция и способ лечения патологических состояний кожи | |
JP2011516585A (ja) | スキンケア組成物およびその使用方法 | |
KR20180078564A (ko) | 피부 진정 및 보습 유지 효과가 우수한 천연 화장료 조성물 | |
KR101382112B1 (ko) | 편백다당체를 함유하는 피부 외용제 조성물 | |
US20220183951A1 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
JPH027287B2 (ko) | ||
KR100322208B1 (ko) | 7-디하이드로콜레스테롤을 함유하는 화장료 조성물 | |
KR100953278B1 (ko) | 항염 및 피부자극완화용 화장료 조성물 | |
KR20180118409A (ko) | 에르고티오네인을 포함하는 영양크림 및 그 제조방법 | |
EP0949919A1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
CN113693966B (zh) | 一种美白淡斑亮采霜及其制备方法 | |
CN113730303A (zh) | 一种以单一类型乳化剂制备多重乳液的方法以及晒后修复冰晶霜 | |
KR100451387B1 (ko) | 피부 탄력 증가와 피부노화 억제 효과를 갖는 원지, 길경,병풀을 함유한 화장료 조성물 및 그 추출물 제조 방법 | |
KR102333132B1 (ko) | 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물 | |
CN107260622B (zh) | 一种生肌敛口滋润保湿防裂膏及其制备方法 | |
KR102097632B1 (ko) | 화장료 조성물 | |
CA1326997C (en) | Composition for cosmetic or pharmaceutical use | |
KR100292143B1 (ko) | 글리콜산과 비타민c를 함유하는 화장용 조성물 | |
KR101917710B1 (ko) | 자초 추출물을 함유하는 피부 온도 조절용 화장료 조성물 | |
KR100450435B1 (ko) | 콜레칼시페롤을함유하는피부노화완화용화장료조성물 | |
JPS63145211A (ja) | ビタミン配合化粧料 | |
WO2017188844A1 (ru) | Лечебно-косметическое средство при комплексном лечении дерматозов | |
KR20160123070A (ko) | 피부 각질 박리용 화장료 조성물 | |
JP2004175767A (ja) | 皮膚障害抑制剤、皮膚障害改善剤,及びそれらを含有する皮膚外用剤 | |
JP2004010757A (ja) | 抗酸化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140113 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20160111 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20170112 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20180105 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 18 |
|
EXPY | Expiration of term |